What Is One of the Best Dividend Stocks to Buy With $1,000 Right Now?
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
dividend-stocksvalue-investing
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A $1,000 investment decision for dividend-focused investors frequently centers on AbbVie Inc. The pharmaceutical company, with a $300 billion market capitalization and a dividend yield of 3.5% as of late May 2026, maintains a Dividend King status. AbbVie announced on 30 May 2026 that it would increase its quarterly payout, marking its 53rd consecutive annual dividend raise. This streak, initiated by its former parent Abbott Laboratories, places AbbVie in an elite group of S&P 500 companies. The yield is anchored by adjusted earnings per share guidance of $13.05 to $13.25 for the full year 2026.
The search for reliable income is sharpened by the current macroeconomic backdrop. The Federal Reserve’s policy rate remains above 4%, and the 10-year Treasury yield trades near 4.3%. In this environment, a stable, growing dividend from a large-cap company becomes a critical component of total return, offsetting valuation pressures from higher discount rates. The last comparable period of elevated rates in the early 2000s saw similar demand for defensive yield, exemplified by Pfizer’s sustained 4% yield through the 2004-2006 hiking cycle while raising its payout annually.
AbbVie’s current appeal is triggered by a specific catalyst chain. The company successfully navigated the 2023 patent cliff for its flagship drug Humira, which once accounted for over 35% of revenue. Its newer immunology and oncology franchises, Skyrizi and Rinvoq, now generate over $20 billion in combined annual sales. This revenue diversification mitigates the single-product risk that often plagues pharmaceutical stocks and provides the cash flow foundation for continued dividend growth. The company’s forward guidance confirms this transition is complete, with mid-single-digit earnings growth projected through 2028.
Four concrete data points define AbbVie’s dividend proposition. The current quarterly dividend is $1.55 per share, translating to an annualized payout of $6.20. At a share price of approximately $177, this provides the 3.5% yield. The company’s dividend payout ratio on adjusted earnings is a sustainable 47%. AbbVie’s five-year dividend compound annual growth rate is 4.8%, exceeding the S&P 500 average of 3.2%. The stock’s performance shows resilience, with a year-to-date total return of 9% versus the Health Care Select Sector SPDR Fund’s 7% gain.
| Metric | AbbVie | S&P 500 Average |
|---|---|---|
| Dividend Yield | 3.5% | 1.4% |
| 5-Year Dividend CAGR | 4.8% | 3.2% |
| Consecutive Annual Increases | 53 years | N/A |
AbbVie’s free cash flow generation, estimated at $23 billion for 2026, comfortably covers the $10 billion annual dividend commitment. This financial strength supports a BBB+ credit rating from S&P Global. The stock’s forward price-to-earnings ratio of 13.5x sits below its 5-year average of 14.2x and the broader pharmaceutical industry average of 15x.
The stability of AbbVie’s dividend has second-order effects across income-focused portfolios and sectors. It draws capital away from lower-yielding utilities and real estate investment trusts, which face higher financing costs. Within healthcare, it pressures peers like Bristol-Myers Squibb and Gilead Sciences, which offer higher yields near 4% but lack AbbVie’s consistent growth profile. Flow data indicates institutional investors have been net buyers of AbbVie for six consecutive quarters, adding over $5 billion in exposure through ETFs and direct holdings, positioning it as a core defensive holding.
A key acknowledged risk is pipeline dependency. While diversified, AbbVie’s growth still relies heavily on Skyrizi and Rinvoq. Any clinical setback or accelerated competitive entry for these drugs could pressure future earnings growth and, by extension, dividend growth prospects. the company’s significant debt load of approximately $70 billion, incurred during its transformational acquisitions, necessitates consistent cash flow to service interest expenses, which could limit financial flexibility during a downturn.
Investors should monitor two specific near-term catalysts. AbbVie’s second-quarter 2026 earnings report, scheduled for 25 July, will provide an update on prescription trends for its key growth drugs and any revisions to full-year cash flow guidance. The next Federal Open Market Committee decision on 17 June will influence the discount rate applied to dividend stocks broadly; a dovish shift could boost capital flows into the sector.
Key technical levels for the stock include a support zone around $170, which aligns with its 200-day moving average, and resistance near $185, its 52-week high. The 10-year Treasury yield remaining above 4.5% could cap multiple expansion for all yield-sensitive equities, including AbbVie. Success in its late-stage neurological disease pipeline, with pivotal data for an Alzheimer’s candidate expected in Q4 2026, represents a potential positive catalyst for long-term growth assumptions.
AbbVie’s dividend is considered exceptionally safe due to its low payout ratio of 47% based on adjusted earnings and its diversified revenue base. Many stocks with yields above 5%, particularly in the energy or telecom sectors, often have payout ratios exceeding 80% of earnings or free cash flow, making them more vulnerable during economic contractions. AbbVie’s status as a Dividend King, requiring over five decades of annual increases, demonstrates a corporate commitment to returning capital that is rare among large-cap companies.
AbbVie’s dividends are classified as qualified dividend income for U.S. taxpayers, provided the shares are held for more than 60 days during the 121-day period surrounding the ex-dividend date. This means the dividends are taxed at the lower long-term capital gains tax rates, which range from 0% to 20%, rather than ordinary income rates. This favorable tax treatment enhances the after-tax income yield for retail investors holding the stock in taxable brokerage accounts.
The company’s dividend growth policy is directly linked to its mid-single-digit earnings growth target. A slowdown would likely reduce the pace of dividend increases, not eliminate them. Management has prioritized the dividend as a key capital allocation pillar. The company’s strong balance sheet and history suggest it would use its cash reserves and use capacity to maintain the annual increase streak during a temporary earnings dip, as it did during the 2020-2021 period, rather than break it.
AbbVie represents a high-conviction dividend growth stock, combining a 3.5% yield with 53 years of proven annual increases.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.